MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 129497-78-5
MCE 国际站:Verteporfin
产品活性:Verteporfin (CL 318952) 是一种用于光动力疗法的光敏剂,用于消除与年龄相关的黄斑变性等疾病相关的眼内异常血管。 Verteporfin 是一种 YAP 抑制剂,可破坏 YAP-TEAD 相互作用。Verteporfin 可以诱导细胞凋亡 (apoptosis)。Verteporfin 是一种自噬 (autophagy) 抑制剂,通过抑制自噬小体形成,在早期阻断自噬。
研究领域:Stem Cell/Wnt | Apoptosis | Autophagy
作用靶点:YAP | Apoptosis | Autophagy
In Vitro: Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 μM, 2.11 μM, and 5.61 μM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T.
In Vivo: Verteporfin (10 mg/kg, c.s.c.) and BMS-354825 significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Apoptosis Compound Library | Stem Cell Signaling Compound Library | Wnt/Hedgehog/Notch Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Macrocyclic Compound Library | Anti-COVID-19 Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Transcription Factor-Targeted Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Cancer Stem Cells Compound Library | Off-patent Drug Library | Mitochondrial Toxicity Compound Library | SY-5609 | BRD4 Inhibitor-18 | 8α-Tigloyloxyhirsutinolide 13-O-acetate | AAPK-25 | Dutasteride-13C6 | Oleic acid-13C | Anticancer agent 120 | Abacavir sulfate | Meloxicam-d3-1 | Thailanstatin D | SB-218078 | Toyocamycin | Sorafenib-d4 | Busulfan | PTC-028 | Dinaciclib | CR-1-31-B | 142I5 | Farudodstat | Ecteinascidin 770 | AT9283 | Staurosporine | SNS-032 | AZA1 | Antitumor agent-96 | Bleomycin A5 | Xevinapant | Mangiferin | Cambinol | hGGPPS-IN-1
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。